Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, Görner M, Kayser S, Krause S, Schliemann C, Gaska T, Kaufmann M, Chemnitz J, Schaich M, Hoellein A, Platzbecker U, Kieser M, Müller-Tidow C, Schlenk RF (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 109
Pages Range: 1973-1976
Journal Issue: 6
DOI: 10.3324/haematol.2023.284346
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Heidelberg
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Aachen (UKA)
Germany (DE)
Klinikum Bielefeld
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Robert-Bosch-Krankenhaus
Germany (DE)
Evangelical Abbey of St. Martin Koblenz
Germany (DE)
Rems-Murr-Kliniken
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Aachen (UKA)
Germany (DE)
Klinikum Bielefeld
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Robert-Bosch-Krankenhaus
Germany (DE)
Evangelical Abbey of St. Martin Koblenz
Germany (DE)
Rems-Murr-Kliniken
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
How to cite
APA:
Jaramillo, S., Krisam, J., Le Cornet, L., Kratzmann, M., Baumann, L., Eissymont, O.,... Schlenk, R.F. (2024). Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia. Haematologica, 109(6), 1973-1976. https://doi.org/10.3324/haematol.2023.284346
MLA:
Jaramillo, Sonia, et al. "Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia." Haematologica 109.6 (2024): 1973-1976.
BibTeX: Download